Enanta Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Enanta Pharmaceuticals Inc (ENTA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 77.3% of the shares are freely tradable; institutional investors hold 92.8%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HHG PLC | 12.99 | 3,784,055 | +1.5 | 03/31/2026 |
| Jupiter Topco LLC | 12.55 | 3,654,920 | +0.0 | 06/30/2026 |
| BlackRock Inc | 11.14 | 3,244,448 | +4.5 | 06/30/2026 |
| Krensavage Asset Management, LLC | 9.84 | 2,866,138 | +0.0 | 06/30/2026 |
| Farallon Capital Management, L.L.C. | 8.30 | 2,418,202 | -15.8 | 06/30/2026 |
| Deep Track Capital, LP | 4.96 | 1,444,167 | -26.2 | 06/30/2026 |
| ADAR1 Capital Management LLC | 4.62 | 1,344,510 | +2,518.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.16 | 1,211,769 | +2.9 | 06/30/2026 |
| Spruce Street Capital LP | 3.74 | 1,088,731 | +16.7 | 06/30/2026 |
| Acadian Asset Management LLC | 3.70 | 1,078,317 | +22.5 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Rottinghaus Scott T. | Chief Medical Officer | 23,787 | 254,521 $ | Aug 8, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 8, 2026 | Rottinghaus Scott T. | Chief Medical Officer | Other | 1,467 | 13.34 | 19,570 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.